![Can Cbd Gummies Make You Test Positive For A Drug Test? [KZEJU5Z7uSj]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-28153356.jpg?resize=150%2C150&ssl=1 "Can Cbd Gummies Make You Test Positive For A Drug Test? 1")
Liraglutide Around Cardiac Surgery: What Four Randomized Trials Did Not Establish
liraglutide cardiac surgery meta-analysis: A meta-analysis of four randomized cardiac-surgery trials found no clear liraglutide effect on 30-day mortality, overall postoperative complications, cardiac adverse events, hypoglycemia, or nausea and vomiting.…
Weekly Medical Cannabis & Science Literature Radar:
medical cannabis research radar: A comprehensive weekly literature index analyzing 20 newly published medical cannabis, cannabinoid, and GLP-1 research studies, clinical trial protocols, and regulatory updates. It keeps the evidence readable for patients…
Insights on Semaglutide Outcomes for MASH Fibrosis in
The semaglutide Japanese MASH fibrosis outcomes from the ESSENCE trial subgroup show improved steatohepatitis resolution at 72 weeks without worsening fibrosis. While fibrosis improvement estimates were imprecise, this prespecified subgroup analysis…
Medical Nutrition Therapy in Incretin-Treated Heart
Medical nutrition therapy HFpEF is critical in managing obesity-related heart failure treated with incretins like semaglutide or tirzepatide. A 2026 review proposes a phase-based nutrition pathway to safeguard muscle and bone during pharmacologic weight…
Is There a Better Day of the Week to Administer Semaglutide
The semaglutide tirzepatide administration timing review finds no clinical evidence favoring a specific day of the week for dosing. Flexible weekly schedules support adherence and patient lifestyle integration. This review guides clinicians and patients…
GLP-1 Drugs and Cervical Fusion: What Conflicting
GLP-1 cervical fusion outcomes were synthesized across 12 retrospective cohorts. Estimates differed by procedure and dataset, and the overall model showed extreme heterogeneity. The evidence does not establish a protective or harmful class-wide effect.
Antidiabetic Drugs and Parkinson’s Risk: What a Nine-Cohort Meta-Analysis Found
antidiabetic drugs Parkinson's risk: Antidiabetic drugs and Parkinson's risk were compared across nine observational cohorts totaling 712,287 patients. No class difference was statistically significant, although GLP-1 and SGLT2 therapies had favorable…
Semaglutide and Cognition in Psychiatric Care: What a 13,007-Patient Cohort Found
semaglutide cognition psychiatric cohort: In a retrospective cohort of 13,007 adults with psychiatric diagnoses, semaglutide initiation was associated with fewer clinician-recorded cognitive signs over 12 months than no antidiabetic treatment, glipizide,…
GLP-1 Drugs and Intracranial Hypertension: What a Low-Certainty Meta-Analysis Found
GLP-1 idiopathic intracranial hypertension evidence was synthesized across eight studies and 13,243 patients. Papilledema, headache, visual, and refractory-disease outcomes favored GLP-1 exposure. Observational dominance, confounding, and heterogeneity…
GLP-1 Plus SGLT2 Therapy: What an Exploratory Cardiorenal Meta-Analysis Found
GLP-1 SGLT2 combination cardiorenal outcomes were examined across 16 randomized trial datasets. Combination use ranked favorably for cardiovascular and kidney outcomes. The mostly nonrandomized subgroup comparisons make the findings hypothesis-generating…